Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Stock Is Sinking Today

By Keith Speights – Jun 10, 2021 at 11:46AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be taking some profits after yesterday's huge gain.

What happened

Shares of Inovio Pharmaceuticals (INO) were sinking 8.8% as of 11:13 a.m. EDT on Thursday. The company didn't announce any new developments, and today's sell-off appears to be due to investors taking profits after Inovio's shares jumped nearly 17% yesterday.

So what

Inovio did have big news on Wednesday that caused the biotech stock to soar. The company announced that it's partnering with Advaccine Biopharmaceuticals Suzhou to evaluate COVID-19 vaccine candidate INO-4800 in a global late-stage clinical study. Advaccine was already collaborating with Inovio to develop and market INO-4800 in the greater China market.

Stock chart with the coronavirus enclosed in an image of the Earth in the background.

Image source: Getty Images.

This expanded partnership was exactly what Inovio needed. The company had planned on financial assistance from the U.S. Department of Defense for a late-stage study of INO-4800. But in April, the Defense Department told Inovio that it wouldn't fund the phase 3 segment of the study because of "the changing environment of COVID-19 with the rapid deployment of vaccines."

It's not all that surprising that investors would engage in some profit-taking. Inovio's shares were up more than 40% over the last month as of the market close on Wednesday, including yesterday's big gain. 

Now what

Inovio and Advaccine plan to advance INO-4800 into the global late-stage study this summer. How Inovio's shares perform will depend on how well this trial goes.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.73 (%)

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.